Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EBITDA: 2022-2025

Historic EBITDA for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to -$7.9 million.

  • InMed Pharmaceuticals' EBITDA fell 5.77% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 10.88%. This contributed to the annual value of -$7.9 million for FY2025, which is 3.10% up from last year.
  • As of FY2025, InMed Pharmaceuticals' EBITDA stood at -$7.9 million, which was up 3.10% from -$8.1 million recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' EBITDA ranged from a high of -$7.9 million in FY2025 and a low of -$18.6 million during FY2022.
  • Its 3-year average for EBITDA is -$8.1 million, with a median of -$8.1 million in 2024.
  • Data for InMed Pharmaceuticals' EBITDA shows a peak YoY soared of 54.91% (in 2023) over the last 5 years.
  • InMed Pharmaceuticals' EBITDA (Yearly) stood at -$18.6 million in 2022, then skyrocketed by 54.91% to -$8.4 million in 2023, then climbed by 2.85% to -$8.1 million in 2024, then climbed by 3.10% to -$7.9 million in 2025.